These results suggest that PSMA-EVs in serum may reflect the development of the neovasculature in primary and metastatic lesions and that the PSMA-EV sandwich ELISA could be used to diagnose and monitor metastatic RCC patients. This evidence concerns the gene FOLH1 and renal cell carcinoma.